

Mechanisms of acquired resistance to targeted cancer t

Future Oncology

8, 999-1014

DOI: [10.2217/fon.12.86](https://doi.org/10.2217/fon.12.86)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. <i>Investigational New Drugs</i> , 2013, 31, 858-870. | 1.2 | 23 |
| 2 | Challenges in cancer vaccine development for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 897-903. | 1.8 | 87 |
| 4 | â€œPathway drug cocktailâ€™™: targeting Ras signaling based on structural pathways. <i>Trends in Molecular Medicine</i> , 2013, 19, 695-704. | 3.5 | 53 |
| 5 | Cancer heterogeneity: implications for targeted therapeutics. <i>British Journal of Cancer</i> , 2013, 108, 479-485. | 2.9 | 753 |
| 6 | Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in <i>CCNE1</i> -Amplified Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5960-5971. | 3.2 | 97 |
| 7 | Inhibiting the RASâ€“PI3K Pathway in Cancer Therapy. <i>The Enzymes</i> , 2013, 34 Pt. B, 107-136. | 0.7 | 20 |
| 8 | Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an <i>AML</i> 1â€• <i>ETO</i> mouse model. <i>EMBO Molecular Medicine</i> , 2013, 5, 1804-1820. | 3.3 | 33 |
| 9 | Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. <i>Oncogenesis</i> , 2013, 2, e83-e83. | 2.1 | 69 |
| 10 | Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2013, 5, 345. | 0.8 | 159 |
| 11 | Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles. <i>Current Pharmaceutical Design</i> , 2014, 20, 23-36. | 0.9 | 115 |
| 12 | Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e204-e212. | 1.8 | 2 |
| 13 | Calcium-channel blocking and nanoparticles-based drug delivery for treatment of drug-resistant human cancers. <i>Therapeutic Delivery</i> , 2014, 5, 763-780. | 1.2 | 8 |
| 14 | Translational hematology. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 487-496. | 0.5 | 0 |
| 15 | Progress and perspectives of biomarker discovery in Chinese medicine research. <i>Chinese Journal of Integrative Medicine</i> , 2014, , 1. | 0.7 | 3 |
| 16 | Epigenetics and chemoresistance in childhood acute lymphoblastic leukemia. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 19-30. | 0.7 | 2 |
| 17 | Resistance to dual blockade of the kinases PI3K and mTOR in <i>KRAS</i> -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. <i>Science Signaling</i> , 2014, 7, ra107. | 1.6 | 30 |
| 18 | Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. <i>Cancer & Metabolism</i> , 2014, 2, 20. | 2.4 | 119 |
| 19 | Resistance acquisition to MDM2 inhibitors. <i>Biochemical Society Transactions</i> , 2014, 42, 752-757. | 1.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 20 | Changing the paradigm: circulating tumor DNA as a "liquid biopsy"™ for clinical biomarker assessments. <i>Clinical Investigation</i> , 2014, 4, 1083-1093. | 0.0 | 1 |
| 21 | Rethinking the war on cancer. <i>Lancet, The</i> , 2014, 383, 558-563. | 6.3 | 231 |
| 22 | The role played by the microenvironment in site-specific metastasis. <i>Cancer Letters</i> , 2014, 352, 54-58. | 3.2 | 54 |
| 23 | Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4427-4453. | 2.9 | 181 |
| 24 | Oncology Drug Discovery: Planning a Turnaround. <i>Cancer Discovery</i> , 2014, 4, 397-404. | 7.7 | 50 |
| 25 | Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1589-1598. | 1.9 | 223 |
| 26 | Epigenetic mechanisms of importance for drug treatment. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 384-396. | 4.0 | 129 |
| 27 | Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. <i>Physiological Genomics</i> , 2014, 46, 699-724. | 1.0 | 26 |
| 28 | Variable NF- κ B pathway responses in colon cancer cells treated with chemotherapeutic drugs. <i>BMC Cancer</i> , 2014, 14, 599. | 1.1 | 28 |
| 29 | Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. <i>Annals of Surgical Oncology</i> , 2014, 21, 610-618. | 0.7 | 15 |
| 30 | An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. <i>Advances in Biological Regulation</i> , 2014, 55, 1-14. | 1.4 | 136 |
| 31 | JUNB promotes the survival of Flavopiridol treated human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 19-24. | 1.0 | 13 |
| 32 | Potential Therapeutic Targets for Oral Cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70. <i>PLoS ONE</i> , 2014, 9, e102610. | 1.1 | 27 |
| 33 | Expression of the mi R β 202/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes. <i>International Journal of Cancer</i> , 2015, 137, 2296-2309. | 2.3 | 34 |
| 35 | Antibody-drug conjugates as novel anti-cancer chemotherapeutics. <i>Bioscience Reports</i> , 2015, 35, . | 1.1 | 327 |
| 36 | TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures. <i>Oncotarget</i> , 2015, 6, 25726-25740. | 0.8 | 13 |
| 37 | Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. <i>Oncotarget</i> , 2015, 6, 32646-32655. | 0.8 | 65 |
| 38 | Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. <i>PLoS ONE</i> , 2015, 10, e0138485. | 1.1 | 48 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 39 | STAT3-Mediated Metabolic Reprogramming in Cellular Transformation and Implications for Drug Resistance. <i>Frontiers in Oncology</i> , 2015, 5, 121. | 1.3 | 106 |
| 40 | Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib. <i>BioMed Research International</i> , 2015, 2015, 1-9. | 0.9 | 19 |
| 42 | Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2015, 51, 291-298. | 0.8 | 136 |
| 43 | Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1177-1201. | 2.4 | 15 |
| 44 | Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. <i>Future Oncology</i> , 2015, 11, 279-293. | 1.1 | 20 |
| 45 | Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy. <i>Oncogene</i> , 2015, 34, 5582-5592. | 2.6 | 34 |
| 46 | Genomic Analysis of Smoothed Inhibitor Resistance in Basal Cell Carcinoma. <i>Cancer Cell</i> , 2015, 27, 327-341. | 7.7 | 316 |
| 47 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in <i>RET</i> -Rearranged Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2238-2248. | 1.9 | 19 |
| 48 | PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. <i>Cancer Cell</i> , 2015, 28, 70-81. | 7.7 | 389 |
| 49 | Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291. | 1.1 | 7 |
| 50 | Isolation and characterization of PDT-resistant cancer cells. <i>Photochemical and Photobiological Sciences</i> , 2015, 14, 1378-1389. | 1.6 | 23 |
| 51 | Intratumoral Heterogeneity: From Diversity Comes Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2916-2923. | 3.2 | 118 |
| 52 | Photochemical activation of drugs for the treatment of therapy-resistant cancers. <i>Photochemical and Photobiological Sciences</i> , 2015, 14, 1465-1475. | 1.6 | 29 |
| 53 | Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance. <i>Lab on A Chip</i> , 2015, 15, 4614-4624. | 3.1 | 23 |
| 54 | c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. <i>Cancer Research</i> , 2015, 75, 4548-4559. | 0.4 | 47 |
| 55 | Directly targeting transcriptional dysregulation in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 686-694. | 12.8 | 95 |
| 56 | Resistance to Photodynamic Therapy in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , . | 0.1 | 8 |
| 57 | Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 27158-27175. | 0.8 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 58 | Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1552. | 1.8 | 27 |
| 59 | The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. <i>Clinical and Translational Science</i> , 2016, 9, 283-292. | 1.5 | 36 |
| 60 | ERRÎ± mediates metabolic adaptations driving lapatinib resistance in breast cancer. <i>Nature Communications</i> , 2016, 7, 12156. | 5.8 | 98 |
| 61 | <i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. <i>Science Translational Medicine</i> , 2016, 8, 369ra175. | 5.8 | 49 |
| 62 | Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 622-631. | 5.1 | 149 |
| 63 | Marriage of antibody-drug conjugate with gold nanorods to achieve multi-modal ablation of breast cancer cells and enhanced photoacoustic performance. <i>RSC Advances</i> , 2016, 6, 46594-46606. | 1.7 | 4 |
| 64 | Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1964-1974. | 1.9 | 47 |
| 65 | CTCs for Biomarker and Companion Diagnostic Development. <i>Current Cancer Research</i> , 2016, , 293-313. | 0.2 | 0 |
| 66 | Activating Mutations in <i>PIK3CB</i> Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110Î². <i>Cancer Research</i> , 2016, 76, 1193-1203. | 0.4 | 52 |
| 67 | Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5563-5586. | 2.9 | 53 |
| 68 | Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , . | 0.2 | 6 |
| 69 | Opportunities and challenges in combination gene cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 35-40. | 6.6 | 64 |
| 70 | Bet on drug resistance. <i>Nature</i> , 2016, 529, 289-290. | 13.7 | 34 |
| 71 | Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 178-196. | 2.0 | 25 |
| 72 | Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma. <i>Nanoscale</i> , 2017, 9, 2755-2767. | 2.8 | 49 |
| 73 | Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 90-97. | 1.5 | 10 |
| 74 | Comparison of patient-derived high and low phosphatidylserine-exposing colorectal carcinoma cells in their interaction with anti-cancer peptides. <i>Journal of Peptide Science</i> , 2017, 23, 56-67. | 0.8 | 4 |
| 75 | MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 328-338. | 1.5 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 76 | Design, synthesis and biological evaluation of regioisomers of 666-15 as inhibitors of CREB-mediated gene transcription. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 994-998. | 1.0 | 14 |
| 77 | Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. <i>Scientific Reports</i> , 2017, 7, 3964. | 1.6 | 57 |
| 78 | Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps. <i>Hormones and Cancer</i> , 2017, 8, 143-156. | 4.9 | 22 |
| 79 | Network pharmacology-based virtual screening of natural products from <i>Clerodendrum</i> species for identification of novel anti-cancer therapeutics. <i>Molecular BioSystems</i> , 2017, 13, 406-416. | 2.9 | 34 |
| 80 | Evolutionary scalpels for dissecting tumor ecosystems. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 69-83. | 3.3 | 10 |
| 81 | Identification of cancer genes that are independent of dominant proliferation and lineage programs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11276-E11284. | 3.3 | 20 |
| 82 | Targeting STAT3 with silibinin to improve cancer therapeutics. <i>Cancer Treatment Reviews</i> , 2017, 58, 61-69. | 3.4 | 86 |
| 83 | Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1457-1474. | 2.4 | 77 |
| 84 | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. <i>Targeted Oncology</i> , 2017, 12, 1-10. | 1.7 | 94 |
| 85 | Targeted therapies in breast cancer: New challenges to fight against resistance. <i>World Journal of Clinical Oncology</i> , 2017, 8, 120. | 0.9 | 227 |
| 86 | MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?. <i>European Journal of Endocrinology</i> , 2018, 178, R155-R181. | 1.9 | 52 |
| 87 | Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. <i>Journal of Controlled Release</i> , 2018, 277, 1-13. | 4.8 | 214 |
| 88 | Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 29-49. | 0.1 | 0 |
| 89 | Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. <i>Cancer Research</i> , 2018, 78, 2127-2139. | 0.4 | 210 |
| 90 | Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. <i>OMICS A Journal of Integrative Biology</i> , 2018, 22, 17-34. | 1.0 | 40 |
| 92 | A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790. | 1.9 | 19 |
| 93 | Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. <i>Annals of Surgery</i> , 2018, 267, 114-121. | 2.1 | 15 |
| 94 | Anti-cancer effects of a novel Pan-RAF inhibitor in a hepatocellular carcinoma cell line. <i>Molecular Medicine Reports</i> , 2018, 17, 6185-6193. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 95 | Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5691-5703. | 1.3 | 30 |
| 96 | SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89. | 1.5 | 18 |
| 98 | The challenge of drug resistance in cancer treatment: a current overview. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 309-318. | 1.7 | 354 |
| 99 | FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and Î±-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2098. | 1.8 | 22 |
| 100 | miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling. <i>EMBO Molecular Medicine</i> , 2018, 10, . | 3.3 | 23 |
| 101 | Role of Resveratrol in Chemosensitization of Cancer. , 2018, , 61-76. | | 4 |
| 103 | Toward Normalization of the Tumor Microenvironment for Cancer Therapy. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986235. | 0.8 | 27 |
| 104 | Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1686-1695. | 7.7 | 75 |
| 105 | Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 51-92. | 0.1 | 1 |
| 107 | Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis. <i>BioMed Research International</i> , 2019, 2019, 1-7. | 0.9 | 5 |
| 108 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38. | 6.9 | 66 |
| 109 | Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid-induced epithelial-mesenchymal transition and stemness in HeLa, 5637 and SCC-15 cells. <i>Oncology Reports</i> , 2019, 41, 3545-3554. | 1.2 | 9 |
| 110 | Effect of mitomycin C on X-ray repair cross complementing group 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8333-8342. | 1.2 | 4 |
| 111 | Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. <i>Molecular Cancer Research</i> , 2019, 17, 642-654. | 1.5 | 24 |
| 112 | A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells. <i>Cancer Research</i> , 2020, 80, 79-90. | 0.4 | 4 |
| 113 | Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. <i>Cancer Research</i> , 2020, 80, 591-601. | 0.4 | 13 |
| 114 | Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer. , 2020, 207, 107454. | | 21 |
| 115 | Hedgehog Pathway Inhibitors for Periocular Basal Cell Carcinoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 13-30. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 116 | miR-21 modulates cisplatin resistance of gastric cancer cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway. <i>Anti-Cancer Drugs</i> , 2020, 31, 385-393. | 0.7 | 40 |
| 117 | The role of autophagy in resistance to targeted therapies. <i>Cancer Treatment Reviews</i> , 2020, 88, 102043. | 3.4 | 89 |
| 118 | Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?. <i>Cancers</i> , 2020, 12, 645. | 1.7 | 21 |
| 119 | Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 138-150. | 1.3 | 11 |
| 120 | Introduction to the Acquisition of Resistance to Targeted Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 1-33. | 0.1 | 2 |
| 121 | Natural and Acquired Resistance to Cancer Therapies. , 2015, , 651-660.e4. | | 1 |
| 123 | Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 155-171. | 0.2 | 88 |
| 124 | Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis. <i>Oncotarget</i> , 2014, 5, 4467-4479. | 0.8 | 20 |
| 125 | MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. <i>Oncotarget</i> , 2015, 6, 28867-28881. | 0.8 | 174 |
| 126 | Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. <i>Oncotarget</i> , 2015, 6, 29991-30005. | 0.8 | 21 |
| 127 | Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. <i>Oncotarget</i> , 2013, 4, 622-635. | 0.8 | 44 |
| 128 | Papel de la superfamilia ABC en la resistencia farmacol3gica. <i>Horizonte Sanitario</i> , 2017, 16, 93. | 0.1 | 1 |
| 129 | Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved. <i>Cureus</i> , 2019, 11, e5383. | 0.2 | 8 |
| 131 | Isolation and Initial Characterization of Resistant Cells to Photodynamic Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 117-145. | 0.1 | 1 |
| 132 | Epithelial Mesenchymal Transition Influence on CTL Activity. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 267-284. | 0.1 | 0 |
| 133 | Osteopontin Gene Expression is Inversely Regulate 5-Fluorouracil Drug Resistance in Colon Cancer. <i>Cancer Research Journal</i> , 2015, 3, 42. | 0.0 | 0 |
| 135 | Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. <i>Nature Biomedical Engineering</i> , 2021, 5, 1306-1319. | 11.6 | 21 |
| 136 | Improving cancer therapy by combining cell biological, physical, and molecular targeting strategies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2013, 25, 7-9. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 138 | Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. <i>Drug Resistance Updates</i> , 2022, 60, 100811. | 6.5 | 13 |
| 139 | Emerging Nano-Based Strategies Against Drug Resistance in Tumor Chemotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 798882. | 2.0 | 23 |
| 140 | De novo Prediction of Cell-Drug Sensitivities Using Deep Learning-based Graph Regularized Matrix Factorization. <i>Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing</i> , 2022, 27, 278-289. | 0.7 | 0 |
| 142 | Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 0, 5, 995-1015. | 0.9 | 0 |
| 144 | Tracking the Development of Cancer Care After 75 Years of Independence: India's Fight Against Cancer Since 1947. <i>Indian Journal of Surgical Oncology</i> , 0, , . | 0.3 | 0 |
| 145 | Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6615. | 1.8 | 29 |
| 147 | Implications of Chemokine Heterogenicity in Cancer Metastasis. , 2023, , 115-136. | | 1 |